DGAP-News: CO.DON AG / Key word(s): Miscellaneous
CO.DON AG: Contract signed for delivery of machinery to Leipzig site

17.01.2018 / 11:00
The issuer is solely responsible for the content of this announcement.


CO.DON AG - Contract signed for delivery of machinery to Leipzig site

+ COMECER FlexycultTM Incubation System for CO.DON's new human cell production plant

Berlin / Teltow, 17.01.2018 - Last week CO.DON AG signed a contract with the COMECER Group from Bologna, Italy, for the delivery of clean room technology to build the new production site in Leipzig. The planned investment volume amounts to approx. 10 million EUR for the area of machinery and equipment.

A period of 10 to 12 months has been set for the modification and installation of the new machinery at the Leipzig site. This will be followed by an intensive validation and qualification process in order to meet the high regulatory standards for pharmaceutical products.

Ralf Jakobs, CEO of CO.DON AG: "We are delighted to have such an experienced partner as COMECER, with its many years of specialist expertise. Together, we have accompanied the development in the past few months and will continue as partners to perform the challenging implementation tasks. CO.DON is entering a new dimension: once all the work is finished the production site will be one of the world's largest and most modern plants for the industrial-scale production of human cells. It will enable us to ensure the supply of the highest quality cell therapy products to our customers in Germany and Europe going forward."

Alessia Zanelli, CEO of COMECER Group: "We are honoured of being part of this great project in what is considered the future of medicine. The fact that our patented technology has been selected by CO.DON makes us proud and certain of the journey we have undertaken in this field."

CO.DON is science-driven biopharmaceutical company committed to research, development and commercialisation of autologous cell therapies for the repair of cartilage defects. Our products use only the patient's own cells and blood, is additive-free and the procedure is minimally invasive. Currently, over 11,000 patients have been treated in 200 clinics in Germany. In July 2017 we received marketing authorisation for the advanced therapy medicinal product, Spherox, from the European Medicine Agency. The shares in CO.DON AG are listed on the Frankfurt Stock Exchange (ISIN: DE000A1K0227). Executive Board: Ralf M. Jakobs.

Further information is available from www.codon.eu

The COMECER GROUP is a developer and manufacturer of high-tech systems in the field of Aseptic Processing and Containment for the Pharmaceutical and Nuclear Medicine Industries, specialising in isolation technology solutions for regenerative medicine and tissue engineering. COMECER's products are used worldwide in hospitals, universities, research institutes, pharma companies and large industrial groups.

Further information is available from www.comecer.com

Investor Relations and Press Contact:
Matthias Meißner, M.A.
Corporate communications / IR / PR
Tel. +49 (0)30 240352330
Fax +49 (0)30 240352309
Email: ir@codon.de



17.01.2018 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: CO.DON AG
Warthestraße 21
14513 Teltow
Germany
Phone: 03328 43460
Fax: 03328 434643
E-mail: info@codon.de
Internet: www.codon.de
ISIN: DE000A1K0227
WKN: A1K022
Listed: Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Stuttgart, Tradegate Exchange

 
End of News DGAP News Service

646017  17.01.2018 

fncls.ssp?fn=show_t_gif&application_id=646017&application_name=news&site_id=zonebourse